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Background. Adults in the United States (US) began receiving the adenovirus vector coronavirus disease 2019 (COVID-19)
vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in February 2021. We evaluated Ad26.COV2.S vaccine effectiveness
(VE) against COVID-19 hospitalization and high disease severity during the ﬁrst 10 months of its use.
Methods. In a multicenter case-control analysis of US adults (≥18 years) hospitalized 11 March to 15 December 2021, we
estimated VE against susceptibility to COVID-19 hospitalization (VEs), comparing odds of prior vaccination with a single dose
Ad26.COV2.S vaccine between hospitalized cases with COVID-19 and controls without COVID-19. Among hospitalized
patients with COVID-19, we estimated VE against disease progression (VEp) to death or invasive mechanical ventilation
(IMV), comparing odds of prior vaccination between patients with and without progression.
Results. After excluding patients receiving mRNA vaccines, among 3979 COVID-19 case-patients (5% vaccinated with
Ad26.COV2.S) and 2229 controls (13% vaccinated with Ad26.COV2.S), VEs of Ad26.COV2.S against COVID-19
hospitalization was 70% (95% conﬁdence interval [CI]: 63–75%) overall, including 55% (29–72%) among immunocompromised
patients, and 72% (64–77%) among immunocompetent patients, for whom VEs was similar at 14–90 days (73% [59–82%]), 91–
180 days (71% [60–80%]), and 181–274 days (70% [54–81%]) postvaccination. Among hospitalized COVID-19 case-patients,
VEp was 46% (18–65%) among immunocompetent patients.
Conclusions. The Ad26.COV2.S COVID-19 vaccine reduced the risk of COVID-19 hospitalization by 72% among
immunocompetent adults without waning through 6 months postvaccination. After hospitalization for COVID-19, vaccinated
immunocompetent patients were less likely to require IMV or die compared to unvaccinated immunocompetent patients.
Keywords. COVID-19; vaccine effectiveness; viral vector vaccines.
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The coronavirus disease 2019 (COVID-19) pandemic, caused
by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), resulted in more than 7 million hospitalizations and 890 000 deaths in the United States through
January 2022 [1]. In February 2021, the SARS-CoV-2 adenovirus vector vaccine (Ad26.COV2.S) from Johnson & Johnson
(Janssen), became the third of 3 vaccines (in addition to
BNT162b2 from Pﬁzer-BioNTech and mRNA-1273 from
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Moderna in December 2020) to be made available in the
United States (US) for adults aged ≥18 years under
Emergency Use Authorization by the Food and Drug
Administration (FDA) [2]. This vaccine employs a recombinant, replication-incompetent adenovirus serotype 26
(Ad26) vector encoding a full-length SARS-CoV-2 spike protein [3] and has been shown in clinical trials [4, 5] and early
observational studies [6, 7] to be effective in preventing severe
COVID-19.
Most people vaccinated against COVID-19 in the United
States have received 1 of the 2 mRNA COVID-19 vaccines
(BNT162b2 or mRNA-1273). However, approximately 18
million doses of the Ad26.COV2.S vaccine have been administered in the United States through February 2022 [1]. Less
frequent use of the Ad26.COV2.S vaccine may be due to later
authorization than mRNA vaccines, limited availability in
many locations, lower estimated vaccine effectiveness (VE)
compared with mRNA vaccines [6], or early reports of adverse events including thrombosis with thrombocytopenia
syndrome (TTS) [8, 9], leading to a temporary suspension
of use from 13–23 April 2021, followed by resumed use
with a warning about the risk of rare blood clotting events
[9]. In December 2021, the US Centers for Disease Control
and Prevention (CDC) issued a preferential recommendation for the BNT162b2 and mRNA-1273 mRNA vaccines
over the Ad26.COV2.S vaccine for primary and booster vaccination [10].
Due to its comparatively limited use, real-world evaluations
of VE for the Ad26.COV2.S vaccine against COVID-19 hospitalization [6] have been lacking compared to those for mRNA
vaccines [11–14]. However, in the United States, the
Ad26.COV2.S vaccine continues to have a role in preventing
COVID-19, including for persons with a contraindication to
receipt of mRNA COVID-19 vaccines [9]. In addition,
Johnson & Johnson plans to donate almost 100 million doses
of Ad26.COV2.S internationally through the COVAX program led by the Coalition for Epidemic Preparedness
Innovations, Gavi Vaccine Alliance, and the World Health
Organization [15]. Therefore, evaluations to assess the realworld effectiveness of the Ad26.COV2.S vaccine against
severe COVID-19 are important. Ongoing use of the
Ad26.COV2.S vaccine in the US population since February
2021 means that evaluations of VE against hospitalization
with sufﬁcient sample size to be meaningful are now possible.
In this analysis, we evaluated 2 forms of vaccine effectiveness
[16] of the Ad26.COV2.S vaccine: (1) effectiveness in preventing susceptibility to COVID-19-associated hospitalization
(VEs), and (2) effectiveness against the progression of
COVID-19 to death or invasive mechanical ventilation
(IMV) within 28 days of hospitalization (VE against disease
progression [VEp]) as a measure of potential disease attenuation among vaccinated patients with COVID-19.
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METHODS

During 11 March 2021 to 15 December 2021, adults admitted
to 21 hospitals comprising the Inﬂuenza or Other Viruses in
the Acutely Ill Network (IVY Network) and who received testing for SARS-CoV-2 were enrolled. The analysis comprised the
timeframe during which the SARS-CoV-2 Alpha (B.1.1.7)
variant predominated (March–June 2021) followed by the
SARS-CoV-2 Delta (B.1.617.2 and AY sublineages) variant
(July–December 2021), and just before Omicron became the
main circulating variant. VEs against COVID-19 hospitalization was evaluated for adults who received a single dose
Ad26.COV2.S vaccine ≥14 days before illness onset. Methods
have been described in detail elsewhere [6, 12–15]. In brief,
case-patients had COVID-19–like illness and received a positive SARS-CoV-2 test result (nucleic acid ampliﬁcation test
[NAAT] or antigen test) within 10 days of illness onset.
Control patients were either “test-negative” controls hospitalized with signs or symptoms of an acute respiratory illness
but testing negative for SARS-CoV-2 by NAAT, or “syndromenegative” controls hospitalized without signs or symptoms of
an acute respiratory illness and testing negative for
SARS-CoV-2 by NAAT. Using standardized case report forms,
interviews with patients or proxies were used to collect demographic and clinical characteristics and electronic medical record (EMR) searches were performed to collect information
about underlying medical conditions. Prior COVID-19 vaccination was veriﬁed primarily through source documentation
(including state vaccination registries, EMRs, and vaccination
record cards) and additionally through self-report including
date and location of vaccination.
For patients hospitalized with COVID-19, we collected data
on their clinical course until the outcome that occurred earliest:
death, hospital discharge, or 28 days after hospital admission if
still admitted. Disease severity was classiﬁed by dividing
COVID-19 case patients into those who experienced death or
required IMV (ie, a composite measure we refer to as progression to high disease severity) and those who did not (ie, no progression to high disease severity). Medical condition categories
were deﬁned using standardized deﬁnitions and obtained
through electronic medical record (EMR) review by trained
surveillance personnel. Persons with immunocompromising
conditions were deﬁned as those with 1 or more of the following: active solid organ cancer; active hematologic cancer (such
as leukemia, lymphoma, or myeloma); human immunodeﬁciency virus (HIV) infection without AIDS; AIDS; congenital
immunodeﬁciency syndrome; previous splenectomy; prior solid organ, stem cell, or bone marrow transplant; use of immunosuppressive medication; systemic lupus erythematosus;
rheumatoid arthritis; psoriasis; scleroderma; or inﬂammatory
bowel disease, including Crohn’s disease or ulcerative colitis
(Supplementary Table 1).

In this analysis of the effects of a single dose AD.26.COV2.S
vaccine, participants who were vaccinated with a single dose
AD.26.COV2.S vaccine and those who were unvaccinated
were analyzed. Enrolled participants who received other vaccine products, such as an mRNA vaccine, or multiple doses
of AD.26.COV2.S were excluded from this analysis. VEs
against COVID-19–associated hospitalization was estimated
using multivariable logistic regression, comparing the odds of
being vaccinated with a single dose Ad26.COV2.S vaccine
among case-patients vs controls, adjusting for potential confounders including admission date (biweekly intervals), geographic region (10 Health and Human Services regions), age
group (18–49, 50–64, or ≥65 years), sex, and self-reported
race and Hispanic ethnicity. VEs were calculated as (1 – adjusted
odds ratio) × 100%. Results were stratiﬁed by age group,
presence of 0 vs ≥1 chronic medical conditions, presence of
0 vs ≥1 immunocompromising conditions, variant period
(Alpha vs Delta), and time since receipt of the vaccine (14–90
days, 91–180 days, and .180 days postvaccination). VEp
against progression to high disease severity was estimated by
restricting analysis to patients hospitalized with COVID-19.
Here we assessed the association between progression to death
or IMV and prior vaccination with Ad26.COV2.S using multivariable logistic regression. These models adjusted for age
group, sex, race, and Hispanic ethnicity, and number of chronic
medical conditions, and results were stratiﬁed by age group and
presence of 0 vs ≥1 immunocompromising conditions. VEp
was calculated as (1 – adjusted odds ratio) × 100%. Analyses
were conducted using R (Vienna, Austria) and STATA
(College Station, Texas, USA). This activity was reviewed by
CDC and conducted in line with with applicable federal law
and CDC policy, for example, 45 C.F.R. part 46.102(l)(2), 21
C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C.
§3501 et seq.
RESULTS

A total of 12 524 adults were enrolled in the IVY study from 11
March through 15 December 2021. Of these, 6316 were excluded because they met one or more exclusion criteria for the current analysis, most commonly because they received a mRNA
vaccine product (n = 6038) as a primary or booster dose. A total of 6208 adults, including 3979 cases with laboratoryconﬁrmed COVID-19 (5% vaccinated with Ad26.COV2.S)
and 2229 controls without COVID-19 (13% vaccinated with
Ad26.COV2.S, P , .002) met inclusion criteria for this analysis.
Compared with control patients, case patients were younger
(median age [interquartile range {IQR}]: 53 [40–64] vs 56
[42–66], P = .002), more likely to be employed (48% vs 26%,
P , .001) and to be employed as a healthcare worker speciﬁcally (5% vs 3%, P = .003) and less likely to be a long-term
care facility resident (2% vs 4%, P , .001), to have been

hospitalized for any cause during the past year (24% vs 57%,
P , .001 to have ≥1 chronic medical condition (68% vs 85%,
P , .001), to currently use tobacco (11% vs 28%, P , .001), or
to report a prior laboratory-conﬁrmed SARS-CoV-2 infection
(3% vs 12%, P , .001). Median (IQR) number of days from
vaccine dose 1 to illness onset was greater for case patients
(140 [85–193]) compared with control patients (127 [69–183]
P = .0049) (Table 1).
VEs Against Hospitalization With COVID-19

Overall adjusted VEs (95% conﬁdence interval [CI]) for a single
dose Ad26.COV2.S vaccine against COVID-19 hospitalization
was 70% (63–75%) and was lower in patients who were immunocompromised (55% [31–72%]) than those who were immunocompetent (72% [64–77%]). Among immunocompetent
patients, VEs was higher (75% [67–82%]) among patients
aged 18–64 years than for those aged ≥65 years (66% [50–
77%]). VEs was similar between periods in which the Alpha
variant (68% [43–83%]) and Delta variant (72% [64–78%]) predominated and remained similar 14–90 days (73% [60–82%]),
91–180 days (71% [59–80%]), and .180 days (70% [53–81%])
postvaccination. Finally, VEs were higher in patients without
chronic medical conditions (86% [74–93%]) than those with
≥1 chronic medical condition (64% [54–73%]) (Figure 1,
Supplementary Table 2).
VEp Against Progression to High Disease Severity

Of 3979 COVID-19 case patients, 3940 (95%) had complete
data on clinical outcomes. Among these patients, COVID-19
patients vaccinated with a single dose Ad26.COV2.S vaccine
were less likely to experience many severe clinical outcomes
compared with unvaccinated COVID-19 patients, including
invasive mechanical ventilation (18% vs 24%, P = .0304), noninvasive ventilation (12% vs 17%, P = .050), high-ﬂow oxygen
therapy (30% vs 40%, P = .011), and vasopressor use (16% vs
23%, P = .025). Vaccinated COVID-19 patients were less likely
to experience high disease severity, deﬁned as the composite of
death or IMV, than unvaccinated COVID-19 patients (20% vs
27%, P = .030). VEp (95% CI) was 36% (7–56%) overall, and
similar for immunocompetent patients (46% [18–65%]), patients aged 18–64 years (31% [11–58%]) and patients aged
≥65 years (47% [4–71%]). No VEp was observed among immunocompromised patients (−29% [−186–42%]) (Figure 2,
Supplementary Table 3).
DISCUSSION

Vaccination with a single dose Ad26.COV2.S vaccine reduced
the risk of COVID-19 hospitalization by more than two-thirds;
this was higher in immunocompetent persons compared with
those who were immunocompromised. Protection against hospitalization was also sustained and stable through 6 or more
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Table 1. Characteristics of Patients Vaccinated With One Dose of Ad26.COV2.S (Johnson & Johnson), COVID-19 Case Patients and Control Patients, IVY
Network
Characteristic, n/N (%)

Total (n = 6208)

Case Patients (n = 3979)

Control Patients (n = 2229)

P-Value

Clinical Group
Vaccinated with 1 dose of Ad26.COV2.S

478/6208 (7.7)

192/3979 (4.8)

286/2229 (12.8)

,.001

Age in years
Median (IQR)

54 (41–65)

53 (40–64)

56 (42–66)

.002

18–49 years

2481/6208 (40.0)

1638/3979 (41.2)

843/2229 (37.8)

50–64 years

2103/6208 (33.9)

1348/3979 (33.9)

755/2229 (33.9)

.006

≥65 years

1624/6208 (26.2)

993/3979 (25.0)

631/2229 (28.3)

Female sex

2939/6208 (47.3)

1873/3979 (47.1)

1066/2229 (47.8)

.569
,.001

Race/ethnicityb
Non-Hispanic White

3208/6208 (51.7)

1985/3979 (49.9)

1223/2229 (54.9)

Non-Hispanic Black

1515/6208 (24.4)

937/3979 (23.5)

578/2229 (25.9)

Hispanic, any race

296/2229 (13.3)

1083/6208 (17.4)

787/3979 (19.8)

Non-Hispanic, all other races

286/6208 (4.6)

192/3979 (4.8)

94/2229 (4.2)

Unknown

116/6208 (1.9)

78/3979 (2.0)

38/2229 (1.7)

US Census Regionc
Northeast

894/6208 (14.4)

592/3979 (14.9)

302/2229 (13.5)

South

2565/6208 (41.3)

1624/3979 (40.8)

941/2229 (42.2)

Midwest

1451/6208 (23.4)

922/3979 (23.2)

529/2229 (23.7)

West

1298/6208 (20.9)

841/3979 (21.1)

457/2229 (20.5)

159/5963 (2.7)

76/3821 (2.0)

83/2142 (3.9)

,.001

1987/4959 (40.1)

1513/3126 (48.4)

474/1833 (25.9)

,.001

LTCF Resident
Employed

222/4959 (4.5)

161/3126 (5.2)

61/1833 (3.3)

≥1 previous hospitalization in the last year

Healthcare worker

2075/5714 (36.3)

882/3633 (24.3)

1193/2081 (57.3)

≥1 chronic medical conditiond

.407

.003
,.001

4619/6207 (74.4)

2716/3978 (68.3)

1903/2229 (85.4)

,.001

Current tobacco use

935/5345 (17.5)

382/3382 (11.3)

553/1963 (28.2)

,.001

Self-reported previous laboratory-conﬁrmed SARS-CoV-2 infection

381/6207 (6.1)

108/3978 (2.7)

273/2229 (12.2)

,.001

Days from vaccine dose 1 to illness onset, median (IQR)

135 (75–185)

140 (84.5–193)

126.5 (69–183)

.049

Data are no./total and no. (%) except where indicated.
Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range; LTFC, long-term care facility; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
Hospitals by region were Northeast: Baystate Medical Center (Springﬁeld, MA), Beth Israel Deaconess Medical Center (Boston, MA), Monteﬁore Medical Center (Bronx, NY); South:
Vanderbilt University Medical Center (Nashville, TN), University of Miami Medical Center (Miami, FL), Emory University Medical Center (Atlanta, GA), Johns Hopkins Hospital (Baltimore,
MD), Wake Forest University Baptist Medical Center (Winston-Salem, NC), Baylor Scott and White Health (Temple, TX); Midwest: University of Iowa Hospitals and Clinics (Iowa City, IA),
University of Michigan Hospital (Ann Arbor, MI), Hennepin County Medical Center (Minneapolis, MN), Barnes-Jewish Hospital (St. Louis, MO), Cleveland Clinic (Cleveland, OH), Ohio
State University Wexner Medical Center (Columbus, OH); West: Stanford University Medical Center (Stanford, CA), UCLA Medical Center (Los Angeles, CA), UCHealth University of
Colorado Hospital (Aurora, CO), Oregon Health and Science University Hospital (Portland, OR), Intermountain Medical Center (Murray, UT), University of Washington (Seattle, WA).
b

Racial and ethnic groups were reported by the patient or proxy.

c

Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan,
Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana,
Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia; West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana,
Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.
d
Chronic medical conditions were obtained through medical chart review by trained personnel and classiﬁed by condition category speciﬁed in the table; a full list of conditions is included in
Supplementary Table 1.

months postvaccination. Moreover, among patients hospitalized with COVID-19, prior vaccination with Ad26.COV2.S,
compared with being unvaccinated, was associated with a lower
risk of severe outcomes including a reduced composite risk of
IMV or death.
The overall VEs against hospitalized COVID-19 observed
in this analysis (70%) was similar to the vaccine efﬁcacy against
severe–critical COVID-19 (75%) demonstrated in a phase
III randomized-controlled trial (RCT) of the 1-dose
Ad26.COV2.S vaccine [5]. As severe outcomes are rare in clinical trials and adults with more severe underlying medical conditions are frequently under-represented in RCTs, results from
this study and other post-marketing observational studies are
S162 • CID 2022:75 (Suppl 2) • Lewis et al

critical to understanding the real-world effectiveness of
COVID-19 vaccines. Importantly, among immunocompetent
COVID-19 case-patients vaccination was associated with a
lower risk (by 46%) of progressing to severe outcomes including death or IMV compared to unvaccinated patients. These results are largely consistent with a cohort study of US veterans
that also found a substantial reduction in severe outcomes including death among Ad26.COV2.S vaccine recipients [7].
Although the VE estimates for Ad26.COV2.S are lower than
those observed for mRNA COVID-19 vaccines [6, 11–14],
the vaccine still provides substantial protection against severe
COVID-19 with little waning for at least six months.
Vaccines using Ad26-based vectors can be stored long-term

Figure 1. Vaccine effectiveness against susceptibility to COVID-19 hospitalization (VEs) for single dose Ad26.COV2.S (Johnson & Johnson) COVID-19 vaccine overall and by
subgroups, IVY Network. Vaccine effectiveness models for immunocompetency, variant period, time since vaccination, and conditions were adjusted for admission date (in
biweekly intervals), US Health and Human Services Region, self-reported race and Hispanic ethnicity, age (18–49, 50–64, and ≥65 years of age), and sex. The model for age
group adjusted for age in years as a continuous variable. Abbreviations: COVID-19, coronavirus disease 2019; VE, vaccine effectiveness.

either frozen or at 2–8°C, enabling product distribution
through existing vaccine supply chains. These vaccines
have also been shown to be stable inside of syringes and
needles, and when subjected to agitation or temperature excursions [17]. Importantly, real-world effectiveness of the
Ad26.COV2.S vaccine could still vary across regions based on
preexisting immunity to Ad26 and its effects on vaccine immunogenicity [17], and further evaluation will be necessary.
The Ad26.COV2.S vaccine showed stable VE over time including among those patients .180 days from vaccination
(100% of which became ill during the period of Delta variant
predominance), suggesting stability of VE over the period predating Omicron variant circulation and reinforcing that the
protection for ≥6 months observed in clinical trials [5] generalizes to a real-world setting with a high prevalence of medically
complex patients. In addition, VEs for the Ad26.COV2.S

vaccine was similar during the Delta-predominant period and
Alpha-predominant periods, suggesting that protection was
observed across 2 different SARS-CoV-2 variants [18, 19], although it may have been reduced against Omicron given the
reduced effectiveness observed for mRNA vaccines [20].
Although a second dose of Ad26.COV2.S, or alternatively, an
mRNA vaccine, ≥2 months from the ﬁrst dose is now recommended for recipients of the Ad26.COV2.S vaccine [17, 21],
our results showed that a single dose Ad26.COV2.S vaccine remained reasonably effective against the Delta variant over time
from vaccination and across periods of different variant predominance. This minimal waning observed here reinforces
preexisting evidence of durable humoral and cellular immune
responses to ad26 vaccines, which use a non-replicating viral
vector that enters the nucleus of cells to induce an immune response [22].
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Figure 2. Vaccine effectiveness against progression to invasive mechanical ventilation or to death within 28 days (VEp) for single dose Ad26.COV2.S (Johnson & Johnson)
COVID-19 Vaccine among adults hospitalized with COVID-19, IVY Network. Vaccine effectiveness models adjusted for age, sex, race, and Hispanic ethnicity, and number of
underlying medical conditions (as 0, 1, 2, 3, or ≥4 categories of conditions). The model for age group adjusted for age in years as a continuous variable. Abbreviation:
COVID-19, coronavirus disease 2019.

We also found that Ad26.COV2.S vaccination attenuated the
likelihood of progression to severe disease among those who
were hospitalized with COVID-19 despite vaccination.
Although VEp against progression to high disease severity
was substantial for immunocompetent persons, the
Ad26.COV2.S vaccine appeared ineffective in preventing progression to high severity in immunocompromised patients.
S164 • CID 2022:75 (Suppl 2) • Lewis et al

Data are lacking on differences in disease attenuation between
immunocompromised and immunocompetent populations.
However, a growing body of literature suggests that immunocompromised patients, including transplant recipients and patients with cancer, have diminished humoral and cellular
immune responses to mRNA and inactivated SARS-CoV-2
vaccines [23–25]. Our results suggest that the immune response

to a single dose Ad26.COV2.S vaccine among immunocompromised patients may be insufﬁcient to attenuate disease severity
in patients who have been hospitalized with COVID-19.
Our ﬁndings must be considered in the context of several
limitations. First, this analysis focused exclusively on protection from a single dose of the Ad26.COV2.S vaccine and
did not evaluate multiple doses of the vaccine or the
Ad26.COV2.S vaccine combined with mRNA vaccine doses.
Additional doses of vaccine would likely increase vaccine effectiveness [17, 21]. Second, although we found overall lower VE
for patients with immunocompromising conditions, this analysis was not powered to look at VE for speciﬁc immunocompromising conditions. Third and relatedly, it is possible that
the types of immunocompromising conditions reported among
patients included in this analysis who received the
Ad26.COV2.S vaccine were different than those who received
mRNA vaccines (ie, due to different vaccine indications for different conditions) and could have affected VEs and VEp for this
subgroup. Fourth, while we did not assess for waning of VE
over time since vaccination within periods of different variant
predominance, no meaningful decline in VE was observed for
either metric. Fifth, VE associated with newly emergent variants was not assessed. Sixth, VE was not assessed against
SARS-CoV-2 infection or mild illness. Finally, although VE estimates were adjusted for relevant potential confounders, residual confounding is possible.
CONCLUSIONS

A single dose Ad26.COV2.S vaccine provided substantial
protection against severe COVID-19 throughout 2021 in this realworld observational study, consistent with vaccine efﬁcacy reported in clinical trials of Ad26.COV2.S conducted in 2020. Although
the observed vaccine effectiveness for Ad26.COV2.S was lower
than that described for mRNA COVID-19 vaccines, a single
dose of Ad26.COV2.S did result in strong protection against severe COVID-19 for at least 6 months in immunocompetent populations. The Ad26.COV2.S vaccine is an important alternative to
mRNA COVID-19 vaccines for those who are unable to receive an
mRNA vaccine.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online.
Consisting of data provided by the authors to beneﬁt the reader, the posted
materials are not copyedited and are the sole responsibility of the authors,
so questions or comments should be addressed to the corresponding
author.
Notes
Disclaimer. The ﬁndings and conclusions in this report are those of the
authors and do not necessarily represent the ofﬁcial position of the Centers
for Disease Control and Prevention.
Financial support. Centers for Disease Control and Prevention funded
this work through payments to each participating institution.

Supplement sponsorship. This article appears as part of the supplement
“Vaccines, Variants, and Vigilance: Strengthening the COVID-19 Public
Health Response Through Partnerships and Collaborations,” supported
by the Infectious Diseases Society of America through Cooperative
Agreement NU50CK000574 with the US Centers for Disease Control
and Prevention.
Potential conﬂicts of interest. M. G.: CDC: Baylor Scott & White Health
(BSWH) US Flu/COVID VE Network, HAIVEN, Synergy studies; CDC-Abt:
BSWH FluVax Trial and RECOVER-PROTECT Cohort Studies;
CDC-Westat: BSWH VISION COVID-Flu VE Study; Janssen: BSWH
Respiratory Syncytial Virus (RSV) Severity App Birth Cohort Study;
Co-Chair of Infectious Diseases and Immunization Committee—Texas
Pediatric Society—Texas Chapter of American Academy of Pediatrics. A. G.:
National Institutes of Health (NIH), Department of Defense; Faron
Pharmaceuticals; AbbVie; D Douin: NIH/National Institute of General
Medical Sciences (NIGMS) Institutional Training Grant. J. C.: NIH and
Department of Defense grants unrelated to this work. T. A. M.: Panelist for
Society of Hospital Medicine Updates in Heart Failure; Board member for
Scott & White Clinic Physicians Board of Directors. K. G.: NECTAR
Executive Committee member ACTIV4-HT; D. C. F.: Cytovale consulting
fees; Medpace Data Safety Monitoring Board. D. N. H.: National Heart,
Lung, and Blood Institute (NIHLBI) participant in the ACTIV4d-Host
Tissue Trial; Chair DSMD—SAFE EVICT Trial of VIT C in
COVID-19. M. N. G.: Grants from NHLBI and Agency for Healthcare
Research and Quality (AHRQ); Consulting fees for Endpoint for scientiﬁc advisory panel; Honoraria—Medicine Grand Rounds from Westchester Medical
Center; Support for attending ATS Board of Directors meeting; Data and Safety
Monitoring Board (DSMB) for Regeneron study and REPLENISH trial. N. J.
J.: IH grants paid to University of Washington Royalty Research Fund;
Department of Defense grants; Medic One Foundation grants; WA
Department of Health expert testimony payment; DSMB for Opticyte, Inc.;
Chair, ACEP Critical Care Section. I. P.: NIH grants; Regeneron
Pharmaceuticals grant; Intermountain Research & Medical Foundation grant;
Asahi Kasei Pharma grant; Janssen Pharmaceuticals grant. S. B.: NIH grants
and Department of Defense grants; DSMB for Hamilton ventilators and
NYU. E. T. M.: Merck grant. A. S. M.: NIH grant. A. K.: NIH grants; United
Therapeutics grants; Eli Lily grants; Johnson & Johnson—BOA Medical—
4DMedical research grants; rA. D.: Center PI for PETAL network through
NHLBI grant; on steering committee for A Lung technologies. J. G. W.:
NIH/NHLBI funding for ACTIV-3 and ACTIV-4 trials; American Board of
Internal Medicine—member of Critical Care Exam Committee. S. Y. C.:
Consulting fees for PureTech Health and Kiniska Pharmaceuticals;
Honoraria for La Jolla. H. M. B.: CDC grant for HCP COVID vaccine effectiveness. J. H. K.: NIAID grant. M. C. E.: Abbott Labs honoraria for speaking on
ASPEN on nutrition in critical illness from COVID. A. L.: grants from CDC,
NIH, and Burroughs Wellcome Fund; consulting fees from Sanoﬁ on antiviral
drugs and for Roche on baloxavir trial steering committee. N. H.: grants from
NIH, Quidel, and Sanoﬁ; Honoraria for speaking at CME event at AAP. C. G.
G.: grants from Campbell Alliance/Syneos Health, Sanoﬁ, CDC, AHRQ, NIH,
and FDA; consulting fees from Merck, Pﬁzer, and Sanoﬁ-Pasteur. T. W. R.:
grants from NIH, Department of Defense and AbbVie; consulting fees for
Cumberland Pharmaceuticals, Inc. and Cytovale, Inc.; DSMB for Sanoﬁ, Inc.;
Immediate Past President—ASPEN; Stock in Cumberland Pharmaceuticals,
Inc. for consulting work. W. B. S.: NIH training grants. C. J. L.: grants from
NIH, Department of Defense; CDC; bioMerieux; Entegrion, Inc.; Endpoint
Health; AbbVie; Patents for risk stratiﬁcation in sepsis and septic shock issued
to Cincinnati Children’s Hospital Medical Center; DSMBs for clinical trials for
Study Principal Investigators; Association for Clinical and Translational Science
(Executive Committee, Immediate Past President, and Board of Directors);
stock options in Bioscape Digita. All other authors report no potential conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the content
of the manuscript have been disclosed.
References
1. Centers for Disease Control and Prevention. COVID data tracker. Available at: https://
covid.cdc.gov/covid-data-tracker/. Accessed 28 September 2021.

Effectiveness of the Ad26.COV2.S COVID-19 Vaccine • CID 2022:75 (Suppl 2) • S165

2. Oliver SE, Gargano JW, Scobie H, et al. The advisory committee on immunization
practices’ interim recommendation for use of Janssen COVID-19 vaccine—
United States, February 2021. MMWR Morb Mortal Wkly Rep 2021; 70:329–32.
3. Livingston EH, Malani PN, Creech CB. The Johnson & Johnson vaccine for
COVID-19. JAMA 2021; 325:1575.
4. Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1–2a trial of
Ad26.COV2.S Covid-19 vaccine. N Engl J Med 2021; 384:1824–35.
5. Sadoff J, Gray G, Vandebosch A, et al. Final analysis of efﬁcacy and safety of
single-dose Ad26.COV2.S. N Engl J Med 2022; 386:847–60.
6. Self WH, Tenforde MW, Rhoads JP, et al. Comparative effectiveness of Moderna,
Pﬁzer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing
COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March–August 2021. MMWR Morb Mortal Wkly Rep
2021; 70:1337–43.
7. Cohn BA, Cirillo PM, Murphy CC, et al. SARS-CoV-2 vaccine protection and
deaths among US veterans during 2021. Science 2022; 375(6578):331–6.
8. Shay DK, Gee J, Su JR, et al. Safety monitoring of the Janssen (Johnson & Johnson)
COVID-19 vaccine—United States, March–April 2021. MMWR Morb Mortal
Wkly Rep 2021; 70:680–4.
9. MacNeil JR, Su JR, Broder KR, et al. Updated recommendations from the advisory
committee on immunization practices for use of the Janssen (Johnson & Johnson)
COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome
among vaccine recipients—United States April 2021. MMWR Morb Mortal Wkly
Rep 2021; 70:651–6.
10. Oliver SE, Wallace M, See I, et al. Use of the Janssen (Johnson & Johnson)
COVID-19 vaccine: updated interim recommendations from the advisory committee on immunization practices—United States December 2021. MMWR
Morb Mortal Wkly Rep 2022; 71:90–5.
11. Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of SARS-CoV-2 mRNA
vaccines for preventing Covid-19 hospitalizations in the United States. Clin Infect
Dis 2021; 74:1515–24.
12. Tenforde MW, Self WH, Naioti EA, et al. Sustained effectiveness of
Pﬁzer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults—United States, March July 2021. MMWR Morb Mortal
Wkly Rep 2021; 70:1156–62.
13. Lewis NM, Naioti EA, Self WH, et al. Effectiveness of mRNA vaccines against
COVID-19 hospitalization by age and chronic medical conditions burden among
immunocompetent US adults, March–August 2021. J Infect Dis 2022; 225:
1694–700.

S166 • CID 2022:75 (Suppl 2) • Lewis et al

14. Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination
and COVID-19 hospitalization and disease severity. JAMA 2021; 326:2043–54.
15. Johnson & Johnson. Almost 100 million doses of Johnson & Johnson COVID-19
vaccine to be donated to lower income countries through COVAX. Available at:
https://www.jnj.com/almost-100-million-doses-of-johnson-johnson-covid-19vaccine-to-be-donated-to-low-income-countries-through-covax. Accessed 2
February 2022.
16. Halloran ME, Longini IM, Struchiner CJ. Overview of vaccine effects and study
designs. In: Halloran ME, Longini IM, Struchiner CJ. Design and analysis of vaccine studies. Statistics for biology and health. London, UK: Springer; 2010:19–45.
17. Moore JP. Approaches for optimal use of different COVID-19 vaccines: issues of
viral variants and vaccine efﬁcacy. JAMA 2021; 325:1251–2.
18. Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly effective mRNA
vaccines for COVID-19 during periods of Alpha and Delta variant prevalence.
BioRxiv 069187 [Preprint]. August 11, 2016 [cited 2017 Jan 12]. Available at:
https://doi.org/10.1101/069187.
19. Bernal JL, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against
the B.1.617.2 (Delta) variant. N Engl J Med 2021; 385:585–94.
20. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association between 3 doses of
mRNA COVID-19 vaccine and symptomatic infection caused by the
SARS-CoV-2 omicron and Delta variants. JAMA 2022; 327:639–51.
21. Mbaeyi S, Oliver SE, Collins JP, et al. The advisory committee on immunization
practices’ interim recommendations for additional primary and booster doses of
COVID-19 vaccines—United States, 2021. MMWR Morb Mortal Wkly Rep 2021;
70:1545–52.
22. Custers J, Kim D, Leyssen M, et al. Vaccines based on replication incompetent
Ad26 viral vectors: standardized template with key considerations for a risk/beneﬁt assessment. Vaccine 2021; 39:3081–101.
23. Bruminhent J, Setthaudom C, Chaumdee P, et al. SARS-CoV-2-speciﬁc humoral
and cell-mediated immune responses after immunization with inactivated
COVID-19 vaccine in kidney transplant recipients (CVIM 1 study). Am J
Transplant 2022; 22:813–22.
24. Stock PG, Henrich TJ, Segev DL, Werbel WA. Interpreting and addressing suboptimal immune responses after COVID-19 vaccination in solid-organ transplant
recipients. J Clin Invest 2021; 131:e151178.
25. Lustig Y, Sapir E, Regev-Yochay G, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre,
longitudinal cohort study in health-care workers. Lancet Resp Med 2021; 9:
999–1009.

